461 related articles for article (PubMed ID: 32890402)
21. The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
Gatti M; Imhof R; Huang Q; Baudis M; Altmeyer M
Cell Rep; 2020 Aug; 32(5):107985. PubMed ID: 32755579
[TBL] [Abstract][Full Text] [Related]
22. Human apurinic/apyrimidinic endonuclease 1 is modified in vitro by poly(ADP-ribose) polymerase 1 under control of the structure of damaged DNA.
Moor NA; Vasil'eva IA; Kuznetsov NA; Lavrik OI
Biochimie; 2020 Jan; 168():144-155. PubMed ID: 31668992
[TBL] [Abstract][Full Text] [Related]
23. ADP-ribose contributions to genome stability and PARP enzyme trapping on sites of DNA damage; paradigm shifts for a coming-of-age modification.
Rouleau-Turcotte É; Pascal JM
J Biol Chem; 2023 Dec; 299(12):105397. PubMed ID: 37898399
[TBL] [Abstract][Full Text] [Related]
24. PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistance.
Kanev PB; Atemin A; Stoynov S; Aleksandrov R
Semin Oncol; 2024; 51(1-2):2-18. PubMed ID: 37714792
[TBL] [Abstract][Full Text] [Related]
25. PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage.
Das BB; Huang SY; Murai J; Rehman I; Amé JC; Sengupta S; Das SK; Majumdar P; Zhang H; Biard D; Majumder HK; Schreiber V; Pommier Y
Nucleic Acids Res; 2014 Apr; 42(7):4435-49. PubMed ID: 24493735
[TBL] [Abstract][Full Text] [Related]
26. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage.
El-Khamisy SF; Masutani M; Suzuki H; Caldecott KW
Nucleic Acids Res; 2003 Oct; 31(19):5526-33. PubMed ID: 14500814
[TBL] [Abstract][Full Text] [Related]
27. Serine-linked PARP1 auto-modification controls PARP inhibitor response.
Prokhorova E; Zobel F; Smith R; Zentout S; Gibbs-Seymour I; Schützenhofer K; Peters A; Groslambert J; Zorzini V; Agnew T; Brognard J; Nielsen ML; Ahel D; Huet S; Suskiewicz MJ; Ahel I
Nat Commun; 2021 Jul; 12(1):4055. PubMed ID: 34210965
[TBL] [Abstract][Full Text] [Related]
28. Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1.
Ryan K; Bolaňos B; Smith M; Palde PB; Cuenca PD; VanArsdale TL; Niessen S; Zhang L; Behenna D; Ornelas MA; Tran KT; Kaiser S; Lum L; Stewart A; Gajiwala KS
J Biol Chem; 2021; 296():100251. PubMed ID: 33361107
[TBL] [Abstract][Full Text] [Related]
29. Differential and Concordant Roles for Poly(ADP-Ribose) Polymerase 1 and Poly(ADP-Ribose) in Regulating WRN and RECQL5 Activities.
Khadka P; Hsu JK; Veith S; Tadokoro T; Shamanna RA; Mangerich A; Croteau DL; Bohr VA
Mol Cell Biol; 2015 Dec; 35(23):3974-89. PubMed ID: 26391948
[TBL] [Abstract][Full Text] [Related]
30. Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins.
Alemasova EE; Lavrik OI
Nucleic Acids Res; 2019 May; 47(8):3811-3827. PubMed ID: 30799503
[TBL] [Abstract][Full Text] [Related]
31. The Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication.
Hanzlikova H; Kalasova I; Demin AA; Pennicott LE; Cihlarova Z; Caldecott KW
Mol Cell; 2018 Jul; 71(2):319-331.e3. PubMed ID: 29983321
[TBL] [Abstract][Full Text] [Related]
32. PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility.
Godon C; Cordelières FP; Biard D; Giocanti N; Mégnin-Chanet F; Hall J; Favaudon V
Nucleic Acids Res; 2008 Aug; 36(13):4454-64. PubMed ID: 18603595
[TBL] [Abstract][Full Text] [Related]
33. PARP inhibitors suppress tumours via centrosome error-induced senescence independent of DNA damage response.
Yue W; Li X; Zhan X; Wang L; Ma J; Bi M; Wang Q; Gu X; Xie B; Liu T; Guo H; Zhu X; Song C; Qiao J; Li M
EBioMedicine; 2024 May; 103():105129. PubMed ID: 38640836
[TBL] [Abstract][Full Text] [Related]
34. CHK2-mediated regulation of PARP1 in oxidative DNA damage response.
Hsu PC; Gopinath RK; Hsueh YA; Shieh SY
Oncogene; 2019 Feb; 38(8):1166-1182. PubMed ID: 30254210
[TBL] [Abstract][Full Text] [Related]
35. Mechanistic insight into the role of Poly(ADP-ribosyl)ation in DNA topology modulation and response to DNA damage.
Matkarimov BT; Zharkov DO; Saparbaev MK
Mutagenesis; 2020 Feb; 35(1):107-118. PubMed ID: 31782485
[TBL] [Abstract][Full Text] [Related]
36. XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA.
Hirota K; Ooka M; Shimizu N; Yamada K; Tsuda M; Ibrahim MA; Yamada S; Sasanuma H; Masutani M; Takeda S
Genes Cells; 2022 May; 27(5):331-344. PubMed ID: 35194903
[TBL] [Abstract][Full Text] [Related]
37. Mitotic functions of poly(ADP-ribose) polymerases.
Slade D
Biochem Pharmacol; 2019 Sep; 167():33-43. PubMed ID: 30910692
[TBL] [Abstract][Full Text] [Related]
38. XRCC1 protects transcription from toxic PARP1 activity during DNA base excision repair.
Adamowicz M; Hailstone R; Demin AA; Komulainen E; Hanzlikova H; Brazina J; Gautam A; Wells SE; Caldecott KW
Nat Cell Biol; 2021 Dec; 23(12):1287-1298. PubMed ID: 34811483
[TBL] [Abstract][Full Text] [Related]
39. PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response.
Kim C; Wang XD; Yu Y
Elife; 2020 Aug; 9():. PubMed ID: 32844745
[TBL] [Abstract][Full Text] [Related]
40. Preventing oxidation of cellular XRCC1 affects PARP-mediated DNA damage responses.
Horton JK; Stefanick DF; Gassman NR; Williams JG; Gabel SA; Cuneo MJ; Prasad R; Kedar PS; Derose EF; Hou EW; London RE; Wilson SH
DNA Repair (Amst); 2013 Sep; 12(9):774-85. PubMed ID: 23871146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
